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AbstrAct
Cyclin dependent kinase 1 (Cdk1) have previously reported correlation with 
cancer growth and a key regulator for cell cycle. Mostly, Cdk1’s function of nucleus 
for cell cycle is well known to be associated with cancer, but cytoplasmic Cdk1’s 
traits are not clearly identified, yet. We revealed that tissue microarray blocks of 
epithelial ovarian cancer (n = 249) showed increased level of cytoplasmic Cdk1  
(p < 0.001), but not in nucleus (p = 0.192) of histologic cell type independently. On 
survival analysis, Cdk1 overexpression conferred a significantly worse prognosis in 
5-year overall survival (Log-rank p = 0.028, Hazard ratio = 2.016, 95% CI = 1.097 
to 4.635). Also, the expression of Cdk1 was increased in ovarian cancer cell lines 
and Gene Expression Omnibus datasets. When the expression and activity of Cdk1 
were inhibited by si-Cdk1 or RO-3306 which is a potent Cdk1 inhibitor, the growth 
of ovarian cancer was diminished. Moreover, combined treatment with RO-3306 and 
cisplatin in ovarian cancer significantly elevated anti-cancer effects than single-agent 
treatment. In conclusion, cytoplasmic Cdk1 expression which was elevated in ovarian 
cancer predicts a poor overall survival. The inhibition of Cdk1 expression and activity 
reduced ovarian cancer growth.
IntroductIon
Cyclin-dependent kinases (CDKs) are important 
cell cycle-regulating proteins, which belong to a serine/
threonine kinase family that comprise of a catalytic kinase 
subunit, together with cyclin protein partners. There are at 
least 13 different CDKs and more than 25 cyclin proteins 
identified to date [1]. However, only Cdk1, 2, 4, and 6 
are directly involved in the cell cycle, and of these, Cdk2, 
4, and 6 are not essential to the cell cycle. Furthermore, 
unlike other Cdks, Cdk1 can promote the cell cycle alone 
and is essential for cell cycle progression and cell division 
[1–3]. Cdk1 regulates the G2 phase as part of a complex 
with cyclin A and is involved in G2/M transition by 
forming a complex with cyclin B. Knockdown of Cdk1 
increases G2/M arrest during the cell cycle and results in 
polyploid cells [1, 2, 4]. 
Cdk1 is highly expressed in various cancers. It has 
been reported that Cdk1 expression or activity is elevated 
in Hodgkin’s lymphomas [5], human colorectal cancer [6], 
prostate cancer [7], gastric lymphoma [8], childhood acute 
lymphoblastic leukemia [9] Therefore, Cdk1 is closely 
related with cancer progression. In particular, it has 
been reported that prognosis is poor in colorectal cancer 
patients with a high nuclear/cytoplasmic ratio of Cdk1 [6]. 
When activity of CDK1 and CDK2 was high in renal cell 
carcinoma patients, recurrence prediction rate was also 
high, while progression-free survival rate was low [10]. 
Therefore, Cdk1 has been introduced as a promising gene 
for targeted therapy that could inhibit progress of the cell 
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cycle in various cancers and induce apoptosis. A number 
of Cdk inhibitors have been developed to date and their 
effects have also been studied. Inhibition of Cdk1 and 
Cdk2 by 6,7,4′-trihydroxyisoflavone inhibited growth 
of HCT-116, a human colon cancer cell line [11], and 
JNJ-7706621, an inhibitor of Cdk1/cyclinB1 and aurora 
kinase effectively reduced growth of transplantable liver 
tumor in combination treatment with paclitaxel [12]. 
Knockdown of cdc2 in glioblastoma U87 and U251 raised 
cell sensitivity to anticancer drugs such as temozolomide, 
resulting in reduction of cell proliferation and promotion 
of apoptosis [13]. 
In general, the cell cycle-associated activity of 
Cdk1 is known to occur in the nucleus. Although previous 
reports suggest that Cdk1 has activity in the cytoplasm 
that is independent of its activity in the nucleus [14, 15], 
its precise mechanism of function and downstream targets 
are not well understood. Moreover, its association with 
ovarian cancer is also not clear.
In this study, we found interesting results that the 
expression of cytoplasmic cdk1 increased in ovarian 
cancer. And also, accumulated cytoplasmic Cdk1 is 
associated with 5-year overall survival in ovarian cancer 
patients. In addition, Cdk1 knockdown or treatment of 
Cdk1 inhibitor resulted in inhibition of cell growth via 
G2/M arrest and apoptosis in ovarian cancer cell lines. 
Finally, these results suggested that cytoplasmic Cdk1 
plays a crucial role of cancer growth in epithelial ovarian 
cancer.
rEsuLts
cdk1 protein is elevated and accumulated in the 
cytoplasm of epithelial ovarian cancer
We previously performed microarray using five 
epithelial ovarian cancer (EOC) cell lines (YDOV-139, 
-157, -161, -13, and -151) that were established in the 
laboratory and four human ovarian surface epithelial 
(HOSE) cells [16–18]. Those microarray results were 
reanalyzed and showed that Cdk1 expression was 
induced in five YDOV cell lines (Fold change of Cdk1 
expression; YDOV-13 = 3.16-fold, YDOV-139 = 7.83-
fold, YDOV-151 = 2.39-fold, YDOV-157 = 3.63-fold, 
YDOV-161 = 2.10-fold). In order to determine if Cdk1 
protein elevation shows clinicopathologic characteristics, 
immunohistochemistry (IHC) of ovarian cancer tissue 
samples was performed and classified by histology. 
Cytoplasmic Cdk1 expression was greater in cancer 
tissues than in normal tissues (Figure 1A–1C). The IHC 
scoring results are summarized in Table 1, which show 
that cytoplasmic Cdk1 expression significantly increased 
in all cell types including clear cell, endometrioid, 
mucinous, and serous types than in normal tissues, 
(*p < 0.05; ***p < 0.001) (Figure 1B and Table 1). 
When the normal tissue and cancer tissue groups were 
compared, cytoplasmic Cdk1 expression in the cancer 
tissue group was 3.44-fold than that in the normal tissue 
group (Figure 1C). In addition, there were 27 cytoplasm-
stained tissue cores (26%), and 51 unstained tissue cores 
(49%) in normal tissues and 167 cytoplasm-stained 
tissue cores (67%) and 22 unstained tissue cores (9%) 
in cancer tissues (Table 2). Thus, while proportion of 
unstained tissues decreased in cancer tissues, proportion 
of cytoplasm-stained tissues increased. In addition, 
cytoplasmic Cdk1 expression increased in accordance 
with progression of tumor grade (p < 0.001) (Table 1). 
The prognosis of the high Cdk1-expression group 
was poor in terms of 5-year overall survival (log rank 
p = 0.028; hazard ratio [HR] = 2.016, 95% CI = 1.097 to 
4.635) (Figure 1D). Patients with advanced FIGO stage, 
poor tumor grade, and serous type, showed significantly 
worse 5-yr overall survival (p = 0.0201, HR = 2.923 
(95% CI = 1.146 to 4.827) ; p = 0.0038, HR = 2.984 (95% 
CI = 1.441 to 6.277) ; p = 0.0124, HR = 3.115 (95% CI = 
1.209 to 4.722), respectively) than patients with early FIGO 
stage, well/moderate tumor grade, and non-serous type 
(Supplementary Figure S3). To verify Cdk1’s expression 
in ovarian cancer cell lines, in same results in tissue 
microarray, expression of Cdk1 was significantly detected 
more in cytoplasm via immunocytochemistry to utilize 
3,3′-diaminobenzidine (DAB) staining (Figure 1E). To 
utilize western blot analysis after subcellular fractionation, 
the expression and activity of Cdk1 in ovarian cancer cell 
lines was strongly detected in cytoplasm (Figure 1F). 
Cyclin B1, known to interact with and regulate the 
activity of Cdk1, is mainly expressed in the cytoplasm of 
ovarian cancer cells. Cyclin A, although highly expressed 
in the nucleus, is also expressed in the cytoplasm. 
In addition, the significantly lower phosphorylation 
status of Tyr15, the Cdk1 inhibitory phosphorylation 
site [19], in the cytoplasm compared with that in the 
nucleus indicates that the cytoplasmic activity of Cdk1 
is very high (Figure 1F). Therefore, it is possible that 
the high activity of cytoplasmic Cdk1 in ovarian cancer 
depends on cytoplasmic cyclins and reduced inhibitory 
phosphorylation.
Thus, as normal tissue progressed to cancer tissue, 
expression of Cdk1, particularly in the cytoplasm, 
increased considerably. And, that cytoplasmic Cdk1 
expression is correlated with ovarian cancer patient’s 
survival rate.
cdk1 and cyclinb1 are overexpressed in 
epithelial ovarian cancer comparing with human 
ovarian surface epithelial cells
Therefore, Cdk1 mRNA level was tested in 
all of EOC cell lines that had been maintained in the 
laboratory, which found that Cdk1 mRNA level was 
higher in EOC cell lines than in HOSE cells (Figure 2A). 
Protein expression level of Cdk1 was also higher in 
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EOC cell lines, consistent with mRNA level (Figure 2B). 
In addition, a cyclinB1 as a Cdk1 binding partner, also 
increased in EOC cell lines as per Cdk1 expression 
(Figure 2B). Like the preceding in Figure 1, these results 
indicate that both of Cdk1’s expression and activity 
were increased in epithelial ovarian cancer cell lines. 
Subsequently, Cdk1 and cyclinB1 expression levels 
were analyzed in four gene expression profiling datasets 
(GES9899, GES26712, GES18520, and GES14407) 
in the Gene Expression Omnibus (GEO). These results 
showed that Cdk1 and cyclinB1 expression levels in four 
microarray datasets were higher in ovarian epithelial cancer 
tissues than in HOSE or LMP tissues, consistent with our 
results of microarray [16–18] and cell lines (Figure 2C). 
Therefore, these results indicate that expression levels of 
Cdk1 with its kinase activity is increased in ovarian cancer, 
and Cdk1 expression might significantly affect ovarian 
cancer cell growth, considering that the intrinsic function 
of Cdk1 is regulation of the cell cycle.
Knockdown of cdk1 by si-cdk1 diminished the 
cell growth in ovarian cancer cell lines
To determine whether elevated Cdk1 protein 
expression affects ovarian cancer growth, Cdk1 expression 
was inhibited by si-Cdk1. First of all, the effects of 
three different sequence of si-Cdk1 were examined in 
OVCAR-3 cells. Si-Cdk1#1 could not reduce Cdk1 
expression. Si-Cdk1#2 and #3 decreased Cdk1 expression 
and caused apoptosis and G2/M arrest (Supplementary 
Figure 4). We selected si-Cdk1#2, which showed the 
strongest apoptotic effects, and observed its effects on 
various ovarian cancer cell lines. Ovarian cancer cell lines 
(OVCA-429, OVCAR-3, SK-OV-3, and OVCA-433) were 
transfected with si-negative control and si-Cdk1 and were 
incubated for 72 h. The si-Cdk1 transfected group of cell 
lines showed lower rate of cell growth than the si-negative 
control transfected group, the reduction rate of cell growth 
being: OVCA-429 = 70.1%, OVCAR-3 = 58.4%, SK-
OV-3 = 29.5%, and OVCA-433 = 49.8% (Figure 3A). 
When ovarian cancer cell lines were treated with si-Cdk1 
for 72 h, the sub-G1 population of OVCAR-3, SK-OV-3, 
and OVCA-433 cells was remarkably larger than that 
of si-negative control transfected cells. Additionally, 
OVCA-429 and SK-OV-3 cells were arrested at G2/M 
phase after transfection with si-Cdk1 (Figure 3B and 3C). 
Western blot analysis of the ovarian cancer cells shows 
an increase in apoptotic markers, such as cleaved PARP, 
cleaved caspase-3, Apaf-1, Bim, Bad, and Bid, in the 
si-Cdk1 transfected cells than in the si-negative control 
cells, in a time-dependent manner (Figure 3D). Previous 
report suggested that the knockdown of Cdk1 induced 
apoptosis in Myc-dependent human breast cancer cell 
[20]. In addition, although the overactivity of E2F1 
increased cell death in cancer cells [21], the expression 
of E2F1 is increased and was correlated with FIGO stage, 
tumor grade in ovarian cancer [22]. Cdk1 increased 
phosphorylation of E2F1 for inhibitory effects of apoptotic 
function. During knock-down of Cdk1 expression, the 
overactivity of E2F1 increased cell death in cancer cells 
[21, 23]. Thus, these results suggest that the knockdown of 
Cdk1 could be induced apoptosis and cell death in ovarian 
cancer cells.
Moreover, phosphorylation of H2A.x (Ser139), 
which is a DNA-damage marker, increased in OVCAR-3, 
SK-OV-3 and OVCA-433 cells. Thus, it seems that DNA 
damage was induced by a reduction in Cdk1 expression 
(Figure 3D). In addition, expression levels of phospho-
BRCA1 (Ser1524) and BRCA1 as a key regulated 
protein in DNA double-strand repair mechanism and 
homologous recombination were diminished in si-Cdk1 
transfected ovarian cancer cell lines, in a time-dependent 
manner (Supplementary Figure 5A). According to these 
observations, ovarian cancer cells could be negatively 
affected by inhibition of Cdk1 expression, because of 
apoptosis and DNA damage.
ro-3306 as a potent cdk1 inhibitor inhibits cell 
growth in oVcA-429 and oVcAr-3 cell lines
To confirm whether RO-3306, a potent Cdk1 
inhibitor, also inhibits growth of ovarian cancer cells, 
OVCA-429 and OVCAR-3 cells were treated with RO-3306 
at various concentrations. It was observed that the growth 
rates of OVCA-429 and OVCAR-3 cells were lower at 
high dose concentration of RO-3306 for up to 9 days. The 
growth rate of OVCA-429 and OVCAR-3 cells showed 
75.3% and 87.7% reductions, respectively with 2.5 μM 
RO-3306 on the 9th day (Figure 4A). To investigate 
whether the decline in the cell growth was caused by cell 
cycle arrest or apoptosis, FACS analysis was performed 
with annexin V and propidium iodide (PI) staining. OVCA-
429 and OVCAR-3 cells were treated with RO-3306 for 
48 h, followed by staining with annexin V and PI, and 
analyzed using FACS. The proportion of the OVCAR-3 
cells in late apoptosis increased from 4.8 to 30.0% with 
10 μM RO-3306, while that of the cells in early apoptosis 
increased from 3.7 to 17.9%. The proportion of OVCA-429 
cells in late apoptosis slightly increased from 3.6 to 7.4%, 
and that of cells in early apoptosis increased considerably 
from 3.6 to 57.4%. Thus, there is a slight difference 
between OVCA-429 and OVCAR-3. (Figure 4B). In the 
cell cycle analysis with PI staining, the RO-3306-treated 
OVCAR-3 cells showed an increase in the sub-G1 (0.8% at 
0 μM to 28.7% at 10 μM) and G2/M population (19.3% at 
0 μM to 55.1% at 10 μM). In case of OVCA-429 cells, the 
G2/M phase was arrested with RO-3306 treatment (18.6% 
at 0 μM to 70.4% at 10 μM), but the sub-G1 population 
was unchanged (Figure 4C and 4D). 
Western blot analysis was performed to verify 
whether there were any changes in the apoptotic markers 
with treatment of RO-3306. After treating with RO-3306 
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Figure 1: cyclin dependent kinase 1 proteins in human ovarian cancer tissue specimens are accumulated in cytoplasm, 
and its expression is correlated with 5-yr survival rate. (A) Representative immunohistochemical staining for Cdk1 in formalin-
fixed, paraffin-embedded epithelial ovarian cancer tissues (EOC). (a, Epithelial; b, Inclusion cysts; c, Fallopian tube; d. Clear cell; e, 
Endometrioid; f, Mucinous; g, High-grade serous). Scale bar = 50 um. (b) IHC staining scores of Cdk1 in each indicated histology of 
EOC and Normal tissue samples. (Epithelial, n = 20; Inclusion cyst, n = 13; Fallopian tube, n = 71; Clear cell, n = 13; Endometrioid, 
n = 27; Mucinous, n = 26; Serous, n = 183). (c) Average IHC scores were combined with normal group (as epithelial, inclusion cyst, 
and fallopian tube; n = 104) and cancer group (as clear cell, endometrioid, mucinous, and serous; n = 249). Results are the means ± S.E. 
***p < 0.001; *p < 0.05, #p > 0.05. (d) Kaplan-Meier survival curve for patients with epithelial ovarian cancer was stratified according to 
cytoplasmic Cdk1 expression. (Low expression of cdk1 is 0 to 1 in IHC score, n = 128; High expression of cdk1 is more then 2, n = 61). 
(E) Representative immunocytochemical staining for Cdk1 in methanol-fixed, ovarian cancer cell lines (OVCA-429, OVCAR-3 and 
SK-OV-3). Scale bar = 100 um. (F) OVCA-429, OVCAR-3 and SK-OV-3 were performed subcellular fractionation from 70% density 
cultured cells and were analyzed via Western blot analysis using an anti-Cdk1 (Thermo Scientific’s antibody), an anti-Cdc2 (Cell Signaling 
Technology’s antibody), an anti-phospho-Cdk1 (Tyr15), an anti-Cyclin B1 and an anti-Cyclin A. Analysis of Lamin B (nuclear marker) 
and β-tubulin (cytoplasmic marker) was performed to assess the efficiency of subcellular fractionation. Whole cell lysate, Wh; Cytoplasm, 
Cy; Nuclear extract, Nu.
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scores in nucleus scores in cytoplasm
p value 
(nucleus/cytoplasm)Mean 95% cI range p value Mean 95% cI range p value
Histology 0.192 < 0.001*
Epithelial 20 0.00 0.45 (–0.20–1.10) 0–6
Inclusion cyst 13 0.15 (–0.07–0.38) 0–1 0.15 (–0.07–0.38) 0–1 1.000
Fallopian tube 71 0.38 (0.26–0.50) 0–2 0.34 (0.21–0.46) 0–2 0.632
Clear cell 13 0.85 (–0.65–2.34) 0–9 2.00 (0.67–3.33) 0–9 0.221
Endometrioid 27 0.37 (0.04–0.70) 0–4 1.52 (0.93–2.10) 0–6 < 0.001*
Mucinous 26 0.35 (0.15–0.54) 0–1 1.04 (0.47–1.60) 0–6 0.021*
Serous 183 0.38 (0.25–0.50) 0–6 1.08 (0.91–1.25) 0–9 < 0.001*
diagnostic category 0.233 < 0.001*
Normal 104 0.28 (0.19–0.37) 0–2 0.34 (0.19–0.48) 0–6 0.511
Cancer 249 0.40 (0.28–0.51) 0–9 1.17 (1.02–1.33) 0–9 < 0.001*
FIGo stage 0.797 0.307
I / II 57 0.47 (0.13–0.81) 0–9 1.39 (0.89–1.88) 0–9 0.003*
III / IV 168 0.38 (0.26–0.49) 0–6 1.10 (0.92–1.26) 0–6 < 0.001*
Recurrent 24 0.38 (–0.15–0.90) 0–6 1.29 (0.82–1.77) 0–4 0.010*
tumor grade 0.123 < 0.001*
1 16 0.81 (0.33–1.30) 0–3 0.63 (0.2–1.06) 0–2 0.542
2 73 0.22 (0.11–0.32) 0–2 1.08 (0.86–1.30) 0–4 < 0.001*
3 81 0.42 (0.14–0.70) 0–9 1.63 (1.24–2.00) 0–9 < 0.001*
x 79 0.46 (0.25–0.66) 0–6 0.91 (0.68–1.14) 0–4 0.004*
chemoresponse 0.599 0.859
Resistance 66 0.45 (0.17–0.74) 0–6 1.21 (0.91–1.51) 0–6 < 0.001*
sensitive 163 0.36 (0.22–0.49) 0–6 1.15 (0.94–1.36) 0–9 < 0.001*
x 20 0.55 (0.08–1.02) 0–4 1.30 (0.71–1.89) 0–4 0.044*
CI, confidence interval; FIGO, International Federation of Gynecology and Obsterics; x, undefined. *p < 0.05.
table 2: number of cdk1 stained cores in ovarian cancer tMA blocks
nucleus cytoplasm unstained total core
Normal 28 (27%) 27 (26%) 51 (49%) 104
Cancer 66 (27%) 167 (67%) 22 (9%) 249
for 24 h, the inhibitory phosphorylation of Cdk1 increased 
dose-dependently both in OVCA-429 and OVCAR-3 
cells (Figure 4E). The levels of apoptotic marker proteins, 
cleaved PARP and cleaved caspase-3, increased both dose- 
and time-dependently with RO-3306 in OVCAR-3 cells 
(Figure 4E and 4F). However, in OVCA-429 cells which 
were treated with 5 μM RO-3306 for 24 hours, the levels 
of these proteins showed only slight increases (Figure 4E). 
Instead, phosphorylation of p38, a stress-dependent kinase, 
and the levels of apoptotic marker proteins Bad, Apaf-1, 
and Bim increased (Figure 4E and 4F). We also confirmed 
that phosphorylation of H2Ax, a DNA damage marker, 
increased in OVCAR-3 cells treated with RO-3306 in a 
dose- and time-dependent manner (Figure 4E and 4F). 
Moreover, phosphorylation of BRCA1, which is involved 
in double-strand break repair, and its reduced expression 
were observed 12 hours after treatment with RO-3306, 
after which both recovered gradually (Supplementary 
Figure 5B). These results indicated that the activity and 
expression of BRCA1 were partially reduced by Cdk1 
inhibition. Accordingly, increased DNA damage could be 
observed.
Finally, these results indicate that inhibition of Cdk1 
activity negatively affected growth of OVCA-429 and 
OVCAR-3 cells through distinct molecular mechanisms, 
consistent with transfection of si-Cdk1.
combined treatment with ro-3306 and cisplatin 
effectively induce apoptosis in oVcA-429 and 
oVcAr-3 cells
To investigate whether the inhibitory effect of 
RO-3306 on cell growth increased on combined treatment 
with cisplatin, OVCA-429 and OVCAR-3 cells were 
treated with either RO-3306 and cisplatin (2.5 μM and 
10 μM), or individually with each drug. Cell viability was 
measured after 5 days using crystal violet assay. It was 
seen that 2.5 μM and 10 μM of the combined treatment 
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Figure 2: the expression levels of cyclin dependent kinase 1 is induced in ovarian cancer cell lines and four Gene 
Expression omnibus dataset. (A) Five human normal ovarian epithelial cell and fourteen ovarian cancer cell lines were extracted at 
70% cell density. Cdk1 mRNA levels were measured by real-time PCR. The fold-change is expressed as a ratio of beta-actin. Results are 
the means ± S.E. n =  3 (left panel). Box plot is corresponded to cdk1 mRNA expression depending on cell types as normal cells or cancer 
cells. *p < 0.05 (right panel). (b) The expression level of Cdk1, Cyclin B1, and β-tubulin were examined via Western blot analyses (left 
panel). Box plot is corresponded to Cyclin B1 protein expression depending on cell types as normal cells or cancer cells. The cyclin B1 
band intensities in western blot were quantified as a ratio of β-tubulin band using the Image J 1.48v software (right panel). **p < 0.01. 
(c) mRNA expression level of Cdk1 and cyclin B1 were analyzed at ovarian cancer patients in four Gene Expression Omnibus (GEO) 
database (GEO accession number; GES9899, GES26712, GES18520, GES14407). P-value compared normal vs cancer or LMP vs cancer. 
Normal = Human ovarian surface epithelial tissue or cell, Cancer = Ovarian cancer tissue, LMP = Low malignant potential. *p < 0.05; **p 
< 0.01; ***p < 0.001.
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effectively inhibited the growth of OVCAR-3 and OVCA-
429 cells, respectively (Figure 5A). To accurately measure 
the rate of apoptosis following combined treatment with 
RO-3306 and cisplatin, FACS analysis was performed 
after staining with annexin V and PI. The result showed 
that late-apoptotic population in OVCA-429 cells 
increased to 19.9% following 10 μM combined treatment, 
in contrast to 3.5 and 16.5% following 10 μM cisplatin 
and RO-3306 individual treatments, respectively. On the 
other hand, the late-apoptotic population in OVCAR-3 
cells increased considerably to 58.2% follwing 10 μM 
combined treatment (Figure 5B). Analysis of the cell cycle 
using PI staining revealed that subjecting the OVCA-
429 cells to 10 μM combined treatment remarkably 
increased the population of sub-G1 and G2/M phase cells. 
In contrast, OVCAR-3 cells showed a greater sub-G1 
population following a 10 μM combined treatment (Figure 
5C and 5D). Western blot revealed that the OVCA-429 
cells subjected to combined treatment showed higher 
phosphorylation of H2A.x, as a DNA damage marker, 
than did the cells treated with a single agent. In addition, 
the level of cleaved PARP and cleaved caspase-3 also 
increased slightly. On the other hand, the level of cleaved 
caspase-3 was higher in OVCAR-3 cells subjected to 
combined treatment than in single-agent treated cells 
(Figure 5E). To determine whether the combined treatment 
with RO-3306 and cisplatin had any effect on in vivo 
mouse model, subcutaneous xenograft of OVCAR-3 cells 
was performed in BALB/c nude mice. Consistent with 
the in vitro results, the xenograft model showed that the 
combined treatment effectively inhibited tumor growth, 
as opposed to treatment with either RO-3306 or cisplatin 
(Figure 5F and 5G). These results show that combined 
treatment with RO-3306, a Cdk1 inhibitor, and cisplatin 
effectively inhibits growth of OVCA-429 and OVCAR-3 
cells.
Figure 3: the si-cdk1 inhibit cell growth via apoptosis and G2/M arrest in ovarian cancer cell lines. (A) Four ovarian 
cancer cell lines (OVCA-429, OVCAR-3, SK-OV-3 and OVCA-433 cells) were transiently transfected with si-Cdk1 and si-negative 
control for 72 h. Cell viability was measured via crystal violet assay. Data are expressed as the means ± S.E. n =  3 (upper panel). Protein 
expression levels of Cdk1 were measured by western blot analysis (bottom panel). (b) Four ovarian cancer cell lines were introduced with 
si-Cdk1 or si-negative control for 72 h. siRNA introduced cells were stained propidium iodide and the cell cycle populations were evaluated 
via FACS analysis. Shown are representative images of 4 separate experiments. (c) Quantification of B. Results are the means ± S.E. n =  4. 
***p < 0.001 (d) Four ovarian cancer cell lines was transfected with si-Cdk1 in indicated time-dependent manner. The expression level of 
indicated protein and the phosphorylation form of H2A.x was examined via Western blot analyses.
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dIscussIon
Previously, we performed microarray analysis with 
cell lines from one mucinous-type and one brenner tumor-
type ovarian cancer, including three from high-grade 
serous type cancers that are representative histotypes of 
ovarian cancer [16–18]. Reanalysis of the microarray 
results revealed up-regulation of Cdk1 expression in the 
ovarian cancer cell lines. Furthermore, all 14 ovarian 
cancer cell lines maintained in our laboratory were found 
to have elevated levels of Cdk1 expression. The results in 
this study were similar to those published to date, which 
show higher Cdk1 expression and activity in Hodgkin’s 
lymphomas, colorectal cancer, prostate cancer, gastric 
lymphoma, and childhood acute lymphoblastic leukemia 
[5–9]. This indicates that ovarian cancer also maintains a 
high level of Cdk1 expression and activity. 
Above all, this study has an interesting point about 
Cdk1’s trait. There is whether cytoplasmic cdk1 which was 
elevated in the ovarian cancer can have activity, or not. 
It is well known that Cdk1 generally has its activity and 
regulates cell cycle in nucleus. But, we demonstrated that 
expression levels of cytoplasmic Cdk1 were increased in 
the results from ovarian cancer patient’s tissue microarray 
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(n = 249) and ovarian cancer cell lines (n = 14). Even 
there are large numbers of TMA slide cores which were 
stained cytoplasmic Cdk1 without nucleus Cdk1 staining 
in ovarian cancer (Figure 1 and Table 1). Also, Inhibitory 
phosphorylation form of Cdk1 (pTyr15) in epithelial 
ovarian cancer cell lines was increased in nucleus than in 
cytoplasm. Besides, cyclin B1 was also highly expressed 
in the cytoplasm of ovarian cancer cells. Cyclin A was 
expressed in the nucleus at high levels, but a certain 
level of expression was also observed in the cytoplasm 
(Figure 1F). In the past studies, Cdk1 in fly embryos 
can be activated in the cytoplasm independently from its 
activation in the nucleus [15]. Also, Cdk1-CycB complex 
is activated in the cytoplasm before its nuclear activation 
in mammalian cultured cells [14]. The expression of Cdk1 
and CyclinB1 is higher in cytoplasm and mitochondria 
than in nucleus via subcellular fractionation in neurons 
and HEK293T cells [24]. When all is said and done, we 
imply that cytoplasmic Cdk1 expressed in ovarian cancer 
can be activated and this altered expression of cytoplasmic 
Cdk1 might influence in ovarian cancer growth. But, the 
precise mechanism whereby cytoplasmic Cdk1’s activity 
modulates ovarian cancer growth remains unknown. 
In addition, although the average cytoplasmic Cdk1 IHC 
score in ovarian cancer TMA slide was relatively low at 
1.17, it was 3.44-fold higher than the average score of 
0.34 in normal tissues (Figure 1C and Table 1). Moreover, 
considering the confirmed roles of Cdk1 from in vitro 
and in vivo experimental data (Figures 3, 5F, and 5G, and 
Supplementary Figure 4) and changes in patient prognosis 
according to Cdk1 expression (Figure 1D), our results 
hold clinical significance and can be used for clinical 
application. 
Besides, Cdk1 is closely related with BRCA because 
BRCA2 is phosphorylated by Cdk1 and Cdk2 to induce 
DNA repair [25, 26]. And, Cdk1 directly induces the 
formation of BRCA1 foci during DNA damage response 
through phosphorylation of a number of serine residues 
in BRCA1 [25]. As per TCGA results, although 33% 
of ovarian cancer patients had alterations in BRCA, 
only a small proportion of patients showed mutations 
in both, BRCA1/2 [27]. In addition, although loss of 
heterozygosity was discovered in 41 ovarian cancer cell 
lines generally used in most laboratories, it was rare to find 
a complete loss of function caused by both of BRCA1 and 
BRCA2 mutations [28]. Most ovarian cancers retain the 
same amount of BRCA function as wild-type, regardless of 
the level of activity. In addition, the rate of recurrence was 
Figure 4: ro-3306 as a potent cdk1 inhibitor inhibits cell growth via induction of apoptosis and G2/M arrest in 
oVcA-429 and oVcAr-3 cells. (A) OVCA-429 and OVCAR-3 were exposed to RO-3306 in indicated time- and dose-dependent 
manner. Cell viability were measured via crystal violet assay. Results are the means ± S.E. n =  3. (b) OVCA-429 and OVCAR-3 were 
treated with 10 uM RO-3306 for 48 h. Detection of apoptosis with annexin V-FITC and propidium iodide (PI) via FACS analysis. (Dot 
plots, Left bottom side is live cells as both annexin V and PI negative. Right bottom side is early apoptosis cells as annexin V positive while 
still excluding PI. Right top side is late apoptosis cells as double positive of annexin V and PI.) (c) Under same condition, cell cycle were 
measured with PI staining via FACS analysis. Shown are representative images of 3 separate experiments. (d) Quantification of C. Results 
are the means ± S.E. n =  3. (E) OVCA-429 and OVCAR-3 were exposed to RO-3306 for 24 h in indicated dose dependent manner, (F) 
10 uM RO-3306 for 12 h up to 48 h. The expression level of the indicated protein and the phosphorylated form of H2A.x and p38 were 
examined via Western blot analyses.
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Figure 5: the combined treatment of ro-3306 and cisplatin effectively induces apoptosis in ovarian cancer. (A) OVCA-492 
and OVCAR-3 were exposed to RO-3306 in the presence of cisplatin for 5 days with combined treatment at 2.5 uM and 10 uM. Then cell 
viability was measured via crystal violet assay. Results are the means ± S.E. n =  3. (b) Under 10 uM concentration of drug treatment for 
3 days, detection of apoptosis with annexin V-FITC and propidium iodide (PI) via FACS analysis in both of cell. (Dot plots, Left bottom 
side is live cells as both annexin V and PI negative. Right bottom side is early apoptosis cells as annexin V positive while still excluding 
PI. Right top side is late apoptosis cells as double positive of annexin V and PI.). (c) Cell cycle were measured with propidium iodide (PI) 
staining via FACS analysis. Shown are representative images of 3 separate experiments. (d) Quantification of C. Results are the means 
(n = 3). (E) OVCA-492 and OVCAR-3 were exposed to RO-3306 in the presence of cisplatin for 48 h. The indicated protein levels were 
measured via Western blot analysis. (F) BALB/c nude mice were inoculated subcutaneously into one flank with 3 × 106 OVCAR-3. Control 
group were four mice and other group were five mice. Drugs were intraperitoneally administered once every 4 days. First day of drug 
injection is seventh day after cell inoculation (Cisplatin, 4 mg / kg; RO-3306, 4 mg / kg), (*p < 0.05; **p < 0.01; ***p < 0.001). (G) Gross 
images of tumor masses from xenograft mice from each group.
Oncotarget49493www.impactjournals.com/oncotarget
reportedly lower in patients with BRCA1/2 mutations in 
triple-negative breast cancer patients [29], and prognosis 
was poor when expression level of BRCA1 was high in 
sporadic epithelial ovarian cancer patients [30]. Thus, it 
is highly probable that since ovarian cancer shows high 
levels of Cdk1 expression and activity, ovarian cancer 
could exhibit resistance to DNA damage agents due to 
increased BRCA activity by Cdk1. Whereupon, it is also 
highly possible that recurrence and malignancy could 
be higher in ovarian cancer with higher levels of Cdk1 
expression and activity, and prognosis of patients could be 
poor as a result.
Actually, when the expression of Cdk1 was reduced 
using si-Cdk1 or Cdk1’s activity was inhibited using 
RO-3306, as a potent Cdk1 inhibitor, DNA damage was 
increased in si-Cdk1 or RO-3306 treated cells (Figures 3 
and 4). In at this point, the activity and expression of 
BRCA1 decreased in a time-dependent manner upon 
si-Cdk1 treatment. Upon RO-3306 treatment, the activity 
of BRCA1 was reduced initially and then recovered 
gradually with time (Supplementary Figure 5A and 5B). 
These results indicate that the inhibition of Cdk1 activity 
or expression can decrease BRCA1 activity, resulting in 
reduced cellular recovery from DNA damage. Further, 
the inhibition can potentially increase sensitivity of the 
cells to anticancer drugs. Actually, when ovarian cancer 
cell lines were treated with a combination of Cisplatin 
and RO-3306, as compared with either treatment alone, 
DNA damage increased (Figure 5E). However, although 
reduced expression of BRCA1 through inhibition of Cdk1 
was observed, inhibitory effects on its activity were not 
(Supplementary Figure 5C). Although the decrease in 
BRCA1 activity upon Cdk1 inhibition was not prominent 
for combined treatment of RO-3360 and Cisplatin, it 
is certain that the inhibition of Cdk1 was significantly 
suppressed cell growth and promoted apoptosis of ovarian 
cancer cell lines treated with cisplatin. In same results, 
in vivo xenograft tumor was effectively inhibited via 
RO-3306 treated with cisplatin (Figure 5F and 5G). 
As a result from this study, high expression of 
cytoplasmic Cdk1 could be a common characteristic 
of ovarian cancer, which is different from normal 
ovarian epithelial cells and be associated with patient’s 
prognosis. Therefore, Cdk1 has potential as a desirable 
candidate gene for effective treatment of ovarian cancer 
and is expected to effectively inhibit ovarian cancer in 
combination with chemotherapeutic agents.
MAtErIALs And MEtHods
Antibodies and reagents
Anti-Cdc2 (#9112), CyclinB1 (#4138), CyclinA 
(#4656), p38 (#9212), cleaved caspase-3 (#9664), Apaf-1 
(#8723), Bim (#2933), Bad (#9239), Bid (#2002), Bax 
(#5023), cleaved PARP (#5625), and BRCA1 (#9010) 
antibodies were purchased from Cell Signaling Technology 
(Danvers, MA). Anti-Cdk1 (A17.1.1) was obtained from 
Thermo scientific (Rockford, IL). Anti-p53 (sc-126), p21 
(sc-397), Lamin B (sc-6216) and β-tubulin (sc-9104) 
antibodies were obtained from Sante Cruz Biotechology 
(Santa cruz, CA). The phospho-specific of H2A.x (Ser139, 
#9718), Cdk1 (Tyr15, #9111), p38 (Thr180/Tyr182, 
#9211) and BRCA1 (Ser1524, #9009) antibodies were 
affinity purified (Cell Signaling Technology). RO-3306 
as Cdk1 selective inhibitor was purchased from Tocris 
Bioscience (Bristol, United Kingdom), and cisplatin was 
obtained from Sigma Aldrich (St. Louis, MO). The stock 
solution of 5mM RO-3306 was dissolved in dimethyl 
sulfoxide (DMSO) and 1.66mM Cisplatin was dissolved 
in 0.9% sodium choloride.
cell culture
YDOV-13, YDOV-139, YDOV-151, YDOV-157, 
YDOV-161 and five human ovarian surface epithelial 
(HOSE) cells, which were established and characterized 
in our laboratory, were cultured as described previously 
[16–18]. SNU-251 and SNU-840 were purchased from 
Korea Cell Line Bank (KCLB, Seoul, Republic of Korea). 
RMUG-S and RMG-I were purchased from Japanese 
Collection of Research Bioresources Cell Bank (JCRB, 
Tokyo, Japan). OVCAR-3, SK-OV-3, and TOV-112D 
were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). OVCA-429 and OVCA-433 were 
maintained in DMEM supplemented with 10% FBS with 
antibiotics. All purchased cell lines were maintained as 
recommended.
Patients and tissue microarray
A total of 249 patients who are diagnosed with 
ovarian cancer at Gangnam Severance Hospital (Seoul, 
Republic of Korea) were enrolled in this study between 
1993 and 2014. Before commencement of this study, 
approval was obtained from the Institutional Review 
Board of Gangnam Severance Hospital (IRB approval 
No. 3-2014-0267), and written consent to participate in the 
study was obtained from each person. Tissue microarray 
block sections (10 μm thickness) were deparaffinized in 
two changes of Histo-Clear™ II (National Diagnostics, 
Atlanta, Gerorgia), rehydrated in graded ethanol, and 
treated for 30 min with 3% H2O2 solution in methanol 
to block endogenous peroxidase. After blocking in 1% 
bovine serum albumin in TBS for 30 minutes, sections 
were incubated with rabbit polyclonal anti-Cdc2 
antibody (#9116, Cell Signaling Technology) diluted to 
1:50 for overnight at 4°C, followed by detection using 
Dako LSAB+ (Dako, Glostrup, Denmark). The reaction 
product was developed with 3,3′-diaminobenzidine 
chromogen solution (Dako). Sections were counterstained 
with hematoxylin and mounted in Faramount Aqueous 
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Mounting Medium (Dako). Appropriate negative 
and positive controls were concurrently performed. 
Representative photomicrographs were recorded using a 
digital camera (Nikon, Tokyo, Japan). Negative controls 
were processed by omitting the primary antibody. 
Human testis tissue was used as a positive control for 
Cdk1 immunoreactivity. Staining for Cdk1 was scored 
as positive when cancer or normal tissue (Epithelium, 
inclusion cyst, and fallopian tube) showed cytoplasmic 
and nucleus immunoreactivity. Cdk1 staining results 
were scored based on staining intensity (0 = negative, 
1 = weak, 2 = moderate, 3 = strong) and the percentage 
of positive cells (0 = 0%, 1 = 1 – 25%, 2 = 26 – 50%, 
3 = 51 – 100% positive cells) (Supplementary Figure 1). 
The cut-off value of Cdk1 expression was determined 
using receiver operating characteristic (ROC) analysis. 
The sensitivity and specificity for discriminating death or 
alive was plotted at each IHC score and the cut-off value 
was established to be the point of the ROC curve where 
the sum of sensitivity and specificity was maximized [31] 
(Supplementary Figure 2). The overall score for each 
patient was further simplified by dichotomizing as either 
cdk1 low expression (overall score of < = 1) or cdk1 high 
expression (score of > = 2) based on 1.5 as the cutoff 
value. Slides were scored in the absence of any clinical 
data, and the final immunostaining score was the average 
score of three expert pathologists.
Immunocytochemisty
Immunocytochemistry was performed on methanol-
fixed OVCA-429, OVCAR-3 and SK-OV-3 cell lines using 
anti-Cdk1 antibody (Thermo Scientific, Rockford, IL) 
and anti-Cdc2 antibody (Cell Signaling Technology, 
Danvers, MA). Briefly, after seeding 5 × 105 cells per 
well in Lab-Tek Chamber slide (Nunc, Rochester, NY), 
cell lines were treated with ice cold methanol for fixation. 
Then the endogenous peroxidase activity was quenched 
by 3% hydrogen peroxide solution for 10 min. Non-
specific binding was prevented by incubation with 5% 
bovine serum albumin and 0.01% Triton X-100 with 
1 × Phosphate buffer saline for 15 min. After that, the 
sections were incubated with anti-Cdk1 antibody (1:300 
dilutions) and anti-Cdc2 antibody (1:630 dilutions) for 
overnight at 4°C. Antibody binding was detected using 
horseradish peroxidase-conjugated secondary antibody 
at 37°C for 30 min. Then sections were visualized by 
3,3′-diaminobenzidine solution (DAKO, Seoul, Republic 
of Korea), counterstained lightly with hematoxylin 
(Sigma-aldrich) dehydrated with ethanol and observed 
using inverted microscopy (model CKX41, Olympus).
subcellular fractionation
Cytoplasm and nuclear fractions were prepared 
using ProteoJET™ Cytoplasmic and Nuclear protein 
Extraction kit (Fermentas, CA) according to the 
manufacturer’s instructions. Briefly, the average ratio of 
protein extract between cytoplasmic fraction and nuclear 
fraction in the subcellular fractionation was 3.08. Thus, 
the whole cell lysate (15 ug), cytoplasmic (15 ug), and 
nuclear extract (5 ug) were separated by SDS-PAGE and 
transferred to a nitrocellulose membrane. Thereafter, 
expression of Cdk1 was detected using an anti-Cdk1 
(Thermo Scientific’s antibody) and an anti-Cdc2 (Cell 
Signal Technology’s antibody) for cross-checking.
Protein extraction and Western blotting
Total cell lysate were isolated using cell lysis buffer 
(150 mM NaCl, 50 mM Tris pH 7.4, 1% NP-40, 1 mM 
EDTA, 1 mM sodium orthovanadate, 1 mM NaF, 1 mM 
sodium pyrophosphate) containing proteinase inhibitor 
cocktail (Roche, Nutley, NJ). Cells were harvested on 
ice, lysates centrifuged, and protein concentrations 
determined with a BCA assay (Sigma-Aldrich). Samples 
were stored at −20°C. Proteins were separated by SDS-
PAGE and electrophoretically transferred from gels to 
0.2 um nitrocellulose membranes (Pall Corporation, 
Washington, NY). The protein bands were visualized 
using a chemiluminescence detection kit (Santa Cruz 
Biotechology) after binding with the HRP-conjugated 
secondary antibody.
sYbr green real-time polymerase chain reaction
Total RNA was extracted from cells using TRIzol 
reagent, chloroform extraction and ethanol precipitation. 
From each sample, 0.8 µg RNA was reverse transcribed 
into cDNA by Maxima First Strand cDNA Synthesis 
Kits for RT-qPCR (Thermo Scientific, Wilmington, DE) 
according to the manufacturer’s suggested protocol. 
SYBR Green real-time polymerase chain reactions 
(PCR) were performed using primer sets. The primers 
for the PCR analysis were as follows: for Cdk1 forward 
(5′-CATGGATTCTTCACTTGTTAAGGT-3′), Cdk1 
reverse (5′-TCCACTTC TGGCCACACTTC-3′), β-actin 
forward (5′-ATTAAGGAGAAGCTGTGCTACGTC-3′), 
and β-actin reverse (5′-ATGATGGAGTTGAAGGTA 
GTTTCG-3′). Reactions were carried out on an ABI 7300 
(Applied Biosystems, Foster City, CA) using TOPreal 
qPCR 2× PreMIX reagents (Enzynomics, Daejeon, 
Republic of Korea). Cycling conditions were 2 min at 
50°C, 10 min at 95°C followed by 40 cycles of 15 sec at 
95°C and 1 min at 60°C. The cytoskelectal gene β-actin 
was used to normalize the quantity of cDNA used for 
PCR. Relative messenger RNA expression was quantified 
using the comparative Ct (∆Ct) method and expressed as 









The cells were seeded at 5 × 105 cells / well in a 
6 cm dish. Medium without antibiotics was added to 
each well so that the cells grew to 70% confluence, 
when the transfection was conducted. The 100 pmole 
siRNA transfection was prepared using Lipofectamine 
RNAiMAX Reagent (Life Technologies) according to 
the manufacturer’s instructions. si-Cdk1#1, si-Cdk1#2, 
and AccuTarget negative control siRNA were purchased 
from BIONEER (Cat. 1028582, 1028584, and SN-1002, 
Seoul, Republic of Korea) and a custom sequence for 
si-Cdk1#3 was designed using Custom RNA service 
by BIONEER. The si-RNA sequences for knock-down 
of Cdk1 expression were as follows: for siCdk1#1 
sense (5′-GAUGUGCUUAUGCAGGAUUdTdT-3′), 
siCdk1#1 anti-sense (5′-AAUCCUGCAUAAGCACAUC 
dTdT-3′), siCdk1#2 sense (5′-CCUGGUCAGUACAUGGA 
UUdTdT-3′), siCdk1#2 anti-sense (5′-AAUCCAUGUAC 
UGACCAGGdTdT-3′) siCdk1#3 sense (5′-GUGGAAUCU 
UUACAGGACUAUdTdT-3′), siCdk1#3 anti-sence (5′-AU 
AGUCCUGUAAAGAUUCCACdTdT-3′). After 72 hours, 
cell lysate was harvested for western blot analysis or 
suspended cell by trypsinization were obtained for FACS 
analysis.
cell viability measurement
Cells were seeded in a 24-well plate at a density 
of 1 × 105 cells. Cells were transfected 100 μM si-Cdk1 
per a well and were treated with RO-3306 and cisplatin 
for indicated periods. Cells were fixed using 10% acetic 
acid solution with 10% methanol and stained with 0.5% 
crystal violet for 1 hour, photographed and extracted using 
1% SDS solution. Crystal violet extract from cells was 
measured absorbance at 595 nm using VERSA max™, 
microplate reader (Molecular Devices, Sunnyvale, CA). 
All experiments were performed in triplicate.
FAcs analysis
The binding of annexin V-FITC to externalized 
phosphatidylserine was used as a measurement of 
apoptotic cells with an Annexin V-FITC/Propidium 
iodide Apoptosis Kit (Biovision, Milpitas, CA) according 
to the manufacturer’s instructions. Briefly, after si-Cdk1 
transfection or treatment of RO-3306 with cisplatin in 
EOC cells for indicated periods, next, 0.1 ml of this cell 
suspension was transferred to a 15-ml tube and incubated 
with 5 ul of Annexin V-FITC and 5 ul of Propidium iodide 
for 15 min at 25°C in the dark. Finally, 0.4 ml of binding 
buffer was added, and samples were analyzed within 1 h 
by a FACScan flow cytometer (BD Biosciences, San Jose, 
CA). Samples were gated on the basis of forward versus 
side scatter for size, and the results are presented as the 
percentage of cells that were viable (Ann-V− PI−), early 
apoptotic (Ann-V+ PI−), or late apoptosis (Ann-V+ PI+). 
And, total cells were harvested via trypsinization, collected 
by centrifugation, and washed in PBS for propidium iodide 
(PI) staining. The cells were subsequently fixed with 70% 
ethanol and resuspended in PBS containing 50 ug/ml PI 
and 0.1 mg/ml RNase A. After the viable cells were sorted, 
fluorescence intensity was measured with FACScan flow 
cytometer (BD Biosciences) using excitation and emission 
wavelengths of 488 and 620 nm, respectively.
In vivo xenograft mouse model
Five-week old female BALB/c nude mice were 
injected with OVCAR-3 cells (3 × 106 cells / mouse) 
in the right flank to form xenograft tumors. Four mice 
were used for control group and five mice were used for 
treated group. Intraperitoneal injections of RO-3306 and 
cisplatin at four-day intervals (4 mg/kg, seven injection 
per mice). Tumor dimensions were measured with digital 
calipers every two days and tumor volume was calculated 
according to the following formula: tumor volume 
(mm3) = length × width2 × 0.5. Tumor xenografts were 
harvested at 28 days after cell transplantation. All animal 
experiments were approved by the Institutional Animal 
Care and Use Committee at Yonsei University in Republic 
of Korea (IACUC Approval No. 2014-0321).
statistical analysis
Results are expressed as the means ± S.E. When 
test of homogeneity of variances was not assumed, the 
Mann-Whitney test or the Kruskal-Wallis test was used 
for continuous variables. Survival curves analysis was 
performed by the Kaplan-Meier method, and statistical 
significance was calculated by the log-rank test. All 
analyses were performed using Graphpad Prism 6 
software. Differences were considered significant at a 
p value of < 0.05. (**p < 0.01; ***p < 0.001; #p>0.05).
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